Abstract
In the last twenty years a depth study on potential pharmaceutical applications of synthetic polymers at proteinlike structure as carrier for macromolecular prodrug production has been performed in academia and in industry. In particular α,β-poly(N-2-hydroxyethyl)-DL-aspartamide (PHEA), α,β-polyaspartylhydrazide (PAHy), poly(glutamic acid) (PGA), poly(aspartic acid) (PAA) and polylysine (PLL) have been extensively studied in this field. In the present review, the use of PHEA, PAHy, PGA as starting materials to prepare macromolecular prodrugs is reported and drug delivery and targeting aspects have been considered.
Keywords: alpha,beta-poly(N-2-hydroxyethyl)-DL-aspartamide, alpha,beta-polyaspartylhydrazide, poly(glutamic acid), carriers, anticancer drugs, pharmaceutical field, nanostructured materials, nanotechnologies, drug molecule, polymeric micelles, chemical conjugation, polyaminoacids, thermal polycondensation, polyaspartic acid (PAA), systematic studies, aα,β:-poly(N-2-hydroxyethyl)-DL-aspartamide, α,β:-polyaspartylhydrazide
Current Topics in Medicinal Chemistry
Title: Macromolecular Prodrugs Based on Synthetic Polyaminoacids: Drug Delivery and Drug Targeting in Antitumor Therapy
Volume: 11 Issue: 18
Author(s): Gennara Cavallaro, Giovanna Pitarresi and Gaetano Giammona
Affiliation:
Keywords: alpha,beta-poly(N-2-hydroxyethyl)-DL-aspartamide, alpha,beta-polyaspartylhydrazide, poly(glutamic acid), carriers, anticancer drugs, pharmaceutical field, nanostructured materials, nanotechnologies, drug molecule, polymeric micelles, chemical conjugation, polyaminoacids, thermal polycondensation, polyaspartic acid (PAA), systematic studies, aα,β:-poly(N-2-hydroxyethyl)-DL-aspartamide, α,β:-polyaspartylhydrazide
Abstract: In the last twenty years a depth study on potential pharmaceutical applications of synthetic polymers at proteinlike structure as carrier for macromolecular prodrug production has been performed in academia and in industry. In particular α,β-poly(N-2-hydroxyethyl)-DL-aspartamide (PHEA), α,β-polyaspartylhydrazide (PAHy), poly(glutamic acid) (PGA), poly(aspartic acid) (PAA) and polylysine (PLL) have been extensively studied in this field. In the present review, the use of PHEA, PAHy, PGA as starting materials to prepare macromolecular prodrugs is reported and drug delivery and targeting aspects have been considered.
Export Options
About this article
Cite this article as:
Cavallaro Gennara, Pitarresi Giovanna and Giammona Gaetano, Macromolecular Prodrugs Based on Synthetic Polyaminoacids: Drug Delivery and Drug Targeting in Antitumor Therapy, Current Topics in Medicinal Chemistry 2011; 11 (18) . https://dx.doi.org/10.2174/156802611797183276
DOI https://dx.doi.org/10.2174/156802611797183276 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Protein and Peptide Drug Delivery Systems
Current Drug Delivery Recent Advances in Pharmacokinetics of Polymeric Excipients Used in Nanosized Anti-Cancer Drugs
Current Drug Metabolism Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology GIST and Breast Cancer: 3 Case Reports and a Review of the Literature
Current Cancer Therapy Reviews Development of a Berberine Loaded Multifunctional Design for the Treatment of Helicobacter pylori Induced Gastric Ulcer
Drug Delivery Letters Detection of Melatonin Production from the Intestinal Epithelium Using Electrochemical Methods
Current Pharmaceutical Design Small Molecule Inhibitors of Multidrug Resistance Gene (MDR1) Expression: Preclinical Evaluation and Mechanisms of Action
Current Cancer Drug Targets Discovery of Novel Small Molecule HDAC1, 2, 3 Inhibitors -- Combined Receptor-Based and Ligand-Based Virtual Screening Strategy
Letters in Drug Design & Discovery Modulation of MicroRNAs by <i>Euphorbia Microsciadia</i> Boiss in MDA-MB-231 Cell Line: New Possibilities in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Polycation-Based Ternary Gene Delivery System
Current Drug Metabolism Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors
Current Pharmaceutical Design Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Soybean and Processed Soy Foods Ingredients, and Their Role in Cardiometabolic Risk Prevention
Recent Patents on Food, Nutrition & Agriculture Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry Adiponectin as a Potential Therapeutic Target for Prostate Cancer
Current Pharmaceutical Design Peptides as Tight Junction Modulators
Current Pharmaceutical Design Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Antisense Oligonucleotide Drug Design
Current Pharmaceutical Design Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials